Targeting SLC7A11-induced nutrient dependency in cancer: mechanisms and preclinical translation

针对 SLC7A11 诱导的癌症营养依赖性:机制和临床前转化

基本信息

  • 批准号:
    10203888
  • 负责人:
  • 金额:
    $ 42.59万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-07-01 至 2025-06-30
  • 项目状态:
    未结题

项目摘要

Project Summary Specific genetic alterations in cancer cells may reprogram their metabolic networks and render them highly dependent on particular nutrients for survival. A mechanistic understanding of nutrient dependency in cancer cells has important implications for cancer treatment because drugs that impair nutrient metabolism may be effective for killing cancer cells that depend on specific nutrients for survival while sparing normal cells. While targeting nutrient dependency has been successful in leukemia, to date there has been limited success in targeting nutrient dependency in solid tumors. Therefore, there is a significant need to understand the mechanisms of action of anti-neoplastic agents that target nutrient dependency in cancer cells. SLC7A11 is an amino acid transporter that enables cystine uptake and its subsequent conversion to cysteine, which is critical for maintaining redox balance and cell survival. SLC7A11 is frequently overexpressed in human cancers, including KEAP1-mutant lung cancers. This application aims to determine the roles and mechanisms of SLC7A11 in regulating nutrient dependency and to therapeutically target nutrient dependency in cancers with aberrant expression of SLC7A11. Our specific aims are: Specific Aim 1: To determine the metabolic mechanisms underlying SLC7A11-induced glucose dependency in cancer cells. Specific Aim 2: To determine the therapeutic potential of inhibiting GLUTs or the PPP in treating tumors with aberrant SLC7A11 expression. The rationale for the proposed research is that studying the roles of SLC7A11 in regulating glucose dependency will not only advance our mechanistic understanding of nutrient dependency in cancer cells but also provide important insights into the development of novel therapeutic strategies to target metabolic vulnerabilities in SLC7A11- overexpressing tumors. Our proposed studies will have significant impact on both our understanding of the fundamental mechanisms of nutrient dependency and our ability to therapeutically target nutrient dependency in cancer treatment.
项目摘要 癌细胞中的特定遗传改变可能会重新编程其代谢网络并使其高度 依赖特定的营养物质生存对癌症营养依赖性的机制性理解 细胞对癌症治疗具有重要意义,因为损害营养代谢的药物可能会 有效杀死依赖特定营养生存的癌细胞,同时保留正常细胞。而 靶向营养依赖已经在白血病中取得了成功,迄今为止, 靶向实体瘤中的营养依赖性。因此,非常需要了解 靶向癌细胞中营养依赖性的抗肿瘤剂的作用机制。SLC 7A 11是一种 一种氨基酸转运蛋白,能够使胱氨酸摄取并随后转化为半胱氨酸,这是至关重要的 以维持氧化还原平衡和细胞存活。SLC 7A 11经常在人类癌症中过表达, 包括KEAP 1突变型肺癌。本申请旨在确定的作用和机制, SLC 7A 11在调节营养物依赖性和治疗靶向癌症中的营养物依赖性中的作用 SLC 7A 11的异常表达。我们的具体目标是:具体目标1:确定代谢机制 潜在的SLC 7A 11诱导的癌细胞中的葡萄糖依赖性。具体目标2:确定治疗 抑制GLUT或PPP在治疗具有异常SLC 7A 11表达的肿瘤中的潜力。的理由 研究SLC 7A 11在调节葡萄糖依赖性中的作用不仅 推进我们对癌细胞营养依赖性的机械理解, 深入了解针对SLC 7A 11代谢脆弱性的新型治疗策略的发展- 过度表达肿瘤我们提出的研究将对我们理解 营养依赖的基本机制和我们治疗营养依赖的能力, 癌症治疗

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Boyi Gan其他文献

Boyi Gan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Boyi Gan', 18)}}的其他基金

Targeting ferroptosis in cancer therapy
癌症治疗中的靶向铁死亡
  • 批准号:
    10581748
  • 财政年份:
    2023
  • 资助金额:
    $ 42.59万
  • 项目类别:
Admin-Core-001
管理核心-001
  • 批准号:
    10942885
  • 财政年份:
    2023
  • 资助金额:
    $ 42.59万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10517141
  • 财政年份:
    2022
  • 资助金额:
    $ 42.59万
  • 项目类别:
Ferroptosis resistance as a key driver in acquired radiation resistance
铁死亡抗性是获得性辐射抗性的关键驱动因素
  • 批准号:
    10707126
  • 财政年份:
    2022
  • 资助金额:
    $ 42.59万
  • 项目类别:
Ferroptosis resistance as a key driver in acquired radiation resistance
铁死亡抗性是获得性辐射抗性的关键驱动因素
  • 批准号:
    10517143
  • 财政年份:
    2022
  • 资助金额:
    $ 42.59万
  • 项目类别:
Acquired Resistance to Therapy and Iron (ARTI) Center
获得性治疗和铁抵抗 (ARTI) 中心
  • 批准号:
    10517140
  • 财政年份:
    2022
  • 资助金额:
    $ 42.59万
  • 项目类别:
Acquired Resistance to Therapy and Iron (ARTI) Center
获得性治疗和铁抵抗 (ARTI) 中心
  • 批准号:
    10707117
  • 财政年份:
    2022
  • 资助金额:
    $ 42.59万
  • 项目类别:
Administrative Supplement: Metabolic Alterations Associated with Acquired Resistance to Ferroptosis in Esophageal Cancer
行政补充:与食管癌铁死亡获得性抗性相关的代谢改变
  • 批准号:
    10830901
  • 财政年份:
    2022
  • 资助金额:
    $ 42.59万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10707118
  • 财政年份:
    2022
  • 资助金额:
    $ 42.59万
  • 项目类别:
Targeting ferroptosis in radioresistance in lung cancer: mechanisms and preclinical translation
靶向肺癌放射抗性中的铁死亡:机制和临床前转化
  • 批准号:
    10531236
  • 财政年份:
    2020
  • 资助金额:
    $ 42.59万
  • 项目类别:

相似海外基金

Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
  • 批准号:
    9975367
  • 财政年份:
    2020
  • 资助金额:
    $ 42.59万
  • 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
  • 批准号:
    16K11932
  • 财政年份:
    2016
  • 资助金额:
    $ 42.59万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
  • 批准号:
    19591274
  • 财政年份:
    2007
  • 资助金额:
    $ 42.59万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
  • 批准号:
    6346309
  • 财政年份:
    2000
  • 资助金额:
    $ 42.59万
  • 项目类别:
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物药理学培训
  • 批准号:
    2720213
  • 财政年份:
    1999
  • 资助金额:
    $ 42.59万
  • 项目类别:
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物药理学培训
  • 批准号:
    6513197
  • 财政年份:
    1999
  • 资助金额:
    $ 42.59万
  • 项目类别:
Training in Pharmacology of Antineoplastic Agents
抗肿瘤药物药理学培训
  • 批准号:
    7101017
  • 财政年份:
    1999
  • 资助金额:
    $ 42.59万
  • 项目类别:
Training in Pharmacology of Antineoplastic Agents
抗肿瘤药物药理学培训
  • 批准号:
    6894842
  • 财政年份:
    1999
  • 资助金额:
    $ 42.59万
  • 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
  • 批准号:
    2885074
  • 财政年份:
    1999
  • 资助金额:
    $ 42.59万
  • 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
  • 批准号:
    6174221
  • 财政年份:
    1999
  • 资助金额:
    $ 42.59万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了